These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35899276)

  • 1. Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for
    Molina KC; Lunowa C; Lebin M; Segerstrom Nunez A; Azimi SF; Krsak M; Mueller SW; Miller MA
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac335. PubMed ID: 35899276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study.
    Jorgensen SCJ; Zasowski EJ; Trinh TD; Lagnf AM; Bhatia S; Sabagha N; Abdul-Mutakabbir JC; Alosaimy S; Mynatt RP; Davis SL; Rybak MJ
    Clin Infect Dis; 2020 Jun; 71(1):1-10. PubMed ID: 31404468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of bloodstream infections caused by methicillin-resistant Staphylococcus aureus at a tertiary care hospital in New York.
    Yasmin M; El Hage H; Obeid R; El Haddad H; Zaarour M; Khalil A
    Am J Infect Control; 2016 Jan; 44(1):41-6. PubMed ID: 26412481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy.
    Frazier JD; Stoudenmire LL; Wagner JL; Thomas GM; Steele GM; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2023 Jul; 62(1):106842. PubMed ID: 37160242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care.
    Johnson TM; Molina KC; Miller MA; Kiser TH; Huang M; Mueller SW
    Int J Antimicrob Agents; 2021 Apr; 57(4):106310. PubMed ID: 33609718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?
    Ben-David D; Novikov I; Mermel LA
    Infect Control Hosp Epidemiol; 2009 May; 30(5):453-60. PubMed ID: 19344266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.
    Burton DC; Edwards JR; Horan TC; Jernigan JA; Fridkin SK
    JAMA; 2009 Feb; 301(7):727-36. PubMed ID: 19224749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections.
    de Kraker ME; Wolkewitz M; Davey PG; Koller W; Berger J; Nagler J; Icket C; Kalenic S; Horvatic J; Seifert H; Kaasch AJ; Paniara O; Argyropoulou A; Bompola M; Smyth E; Skally M; Raglio A; Dumpis U; Kelmere AM; Borg M; Xuereb D; Ghita MC; Noble M; Kolman J; Grabljevec S; Turner D; Lansbury L; Grundmann H;
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1598-605. PubMed ID: 21220533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer.
    Jorgensen SCJ; Lagnf AM; Bhatia S; Shamim MD; Rybak MJ
    J Antimicrob Chemother; 2019 Feb; 74(2):489-498. PubMed ID: 30418557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus.
    Huang V; Cheung CM; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2010 Jan; 35(1):25-9. PubMed ID: 19900792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
    Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
    Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalbavancin Use in Persons Who Use Drugs May Increase Adherence Without Increasing Cost.
    Russo TA; Ritchie HR; Schimmel JJ; Lorenzo MP
    J Pharm Technol; 2024 Feb; 40(1):3-9. PubMed ID: 38318254
    [No Abstract]   [Full Text] [Related]  

  • 16. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated bloodstream infections in Korea.
    Park SH; Park C; Yoo JH; Choi SM; Choi JH; Shin HH; Lee DG; Lee S; Kim J; Choi SE; Kwon YM; Shin WS
    Infect Control Hosp Epidemiol; 2009 Feb; 30(2):146-55. PubMed ID: 19128184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant
    Zasowski EJ; Trinh TD; Claeys KC; Lagnf AM; Bhatia S; Klinker KP; Veve MP; Estrada SJ; Johns ST; Sawyer AJ; Huang V; LaFrance B; Levine DP; Kaye KS; Davis SL; Rybak MJ
    Open Forum Infect Dis; 2022 Mar; 9(3):ofab606. PubMed ID: 35146040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and clinical characteristics of Staphylococcus aureus bloodstream infections in a tertiary-care center in Mexico City: 2003-2007.
    Ponce-de-León A; Camacho-Ortiz A; Macías AE; Landín-Larios C; Villanueva-Walbey C; Trinidad-Guerrero D; López-Jácome E; Galindo-Fraga A; Bobadilla-del-Valle M; Sifuentes-Osornio J
    Rev Invest Clin; 2010; 62(6):553-9. PubMed ID: 21416781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus.
    Harbarth S; Rutschmann O; Sudre P; Pittet D
    Arch Intern Med; 1998 Jan; 158(2):182-9. PubMed ID: 9448557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study.
    Laupland KB; Lyytikäinen O; Søgaard M; Kennedy KJ; Knudsen JD; Ostergaard C; Galbraith JC; Valiquette L; Jacobsson G; Collignon P; Schønheyder HC;
    Clin Microbiol Infect; 2013 May; 19(5):465-71. PubMed ID: 22616816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.